Center for Scientific Review; Notice of Closed Meetings, 135-136 [2017-28226]
Download as PDF
<![CDATA[
135
Federal Register / Vol. 83, No. 1 / Tuesday, January 2, 2018 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
(in hours)
Type of respondent
FDA Form No.2
Cosmetics ...........................
Food ....................................
FDA 3613d .........................
FDA 3613e, 3613g, 3613l ..
270
881
3
5
810
4,405
0.5
0.5
405
2,203
Total .............................
.............................................
........................
........................
........................
........................
2,608
Total hours
1 There
2 All
are no capital costs or operating and maintenance costs associated with this collection of information.
forms are submitted electronically via the Certificate Application Process (CAP).
We have revised the currently
approved burden estimate for the
information collection to reflect the
elimination of paper-based forms.
Specifically, and based on our
experience with the information
collection, we have reduced the
estimated time to prepare a submission
from 1.5 hours to 0.5 hour. The previous
estimate was based on the time
necessary to prepare a paper
submission, but all firms requesting
export certificates now provide
submissions electronically via CAP. We
believe that the time to prepare an
electronic submission is under 0.25
hour, but are estimating 0.5 hour as a
conservative approach to address all
scenarios. We base our estimates of the
total annual responses on our
experience with certificate applications
received in the past 3 fiscal years.
We expect that most firms requesting
export certificates in the next 3 years
will choose to take advantage of the
option of electronic submission via
CAP. If a firm is unable to submit their
information via CAP, they may contact
CFSAN and request assistance. CFSAN
will assist firms in entering their
information into the electronic system
so that the firm may receive their export
certificates in a timely manner. Our
burden estimates in Table 1 are based
on the expectation of 100 percent
participation in the electronic
submission process. Providing the
opportunity to submit the information
in electronic format has reduced our
previous estimates for the time to
prepare each submission.
daltland on DSKBBV9HB2PROD with NOTICES
Dated: December 26, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–28258 Filed 12–29–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
19:54 Dec 29, 2017
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group;
Neuroendocrinology, Neuroimmunology,
Rhythms and Sleep Study Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: New Orleans Marriott, 555 Canal
Street, New Orleans, LA 70130.
Contact Person: Michael Selmanoff, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164,
MSC 7844, Bethesda, MD 20892, 301–435–
1119, mselmanoff@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Macromolecular Structure
and Function A Study Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza Dallas Downtown,
1015 Elm Street, Dallas, TX 75202.
Contact Person: David R. Jollie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7806, Bethesda, MD 20892, (301)–408–
9072, jollieda@csr.nih.gov.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Medical Imaging
Study Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Catamaran Resort, 3999 Mission
Boulevard, San Diego, CA 92109.
Contact Person: Xiang-Ning Li, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5112,
MSC 7854, Bethesda, MD 20892, 301–435–
1744, lixiang@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Social Sciences and Population Studies A
Study Section.
Date: February 1, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marines’ Memorial Club & Hotel,
609 Sutter Street, San Francisco, CA 94102.
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Atherosclerosis and Inflammation of the
Cardiovascular System Study Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Delfina Santa Monica
Hotel, 530 West Pico Boulevard, Santa
Monica, CA 90405.
Contact Person: Natalia Komissarova,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
MSC 7846, Bethesda, MD 20892, 301–435–
1206, komissar@mail.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Developmental Therapeutics Study
Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Bayside, 4875 North
Harbor Drive, San Diego, CA 92106.
Contact Person: Sharon K. Gubanich,
Ph.D., Scientific Review Officer, Center for
E:\FR\FM\02JAN1.SGM
02JAN1
136
Federal Register / Vol. 83, No. 1 / Tuesday, January 2, 2018 / Notices
daltland on DSKBBV9HB2PROD with NOTICES
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301) 408–
9512, gubanics@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Psychosocial Development, Risk and
Prevention Study Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Arlington, 1325 Wilson
Boulevard, Arlington, VA 22209.
Contact Person: Anna L. Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Biomaterials and Biointerfaces Study
Section.
Date: February 1–2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Capital View, 2850
South Potomac Avenue, Arlington, VA
22202.
Contact Person: Joseph D. Mosca, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158,
MSC 7808, Bethesda, MD 20892, (301) 408–
9465, moscajos@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Kidney, Nutrition, Obesity and Diabetes
Study Section.
Date: February 1–2, 2018.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Wardman Park Washington
DC Hotel, 2660 Woodley Road NW,
Washington, DC 20008.
Contact Person: Fungai Chanetsa, MPH,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3135,
MSC 7770, Bethesda, MD 20892, 301–408–
9436, fungai.chanetsa@nih.hhs.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 26, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–28226 Filed 12–29–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:54 Dec 29, 2017
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated January 23, 2017 (82
FR 7920), the following HHS-certified
laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190 (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
844–486–9226
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823 (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130 (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
E:\FR\FM\02JAN1.SGM
02JAN1
]]>Agencies
[Federal Register Volume 83, Number 1 (Tuesday, January 2, 2018)]
[Notices]
[Pages 135-136]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-28226]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Integrative, Functional and Cognitive
Neuroscience Integrated Review Group; Neuroendocrinology,
Neuroimmunology, Rhythms and Sleep Study Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: New Orleans Marriott, 555 Canal Street, New Orleans, LA
70130.
Contact Person: Michael Selmanoff, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164, MSC 7844, Bethesda, MD
20892, 301-435-1119, [email protected].
Name of Committee: Biological Chemistry and Macromolecular
Biophysics Integrated Review Group; Macromolecular Structure and
Function A Study Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Crowne Plaza Dallas Downtown, 1015 Elm Street, Dallas, TX
75202.
Contact Person: David R. Jollie, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166, MSC 7806, Bethesda, MD
20892, (301)-408-9072, [email protected].
Name of Committee: Surgical Sciences, Biomedical Imaging and
Bioengineering Integrated Review Group; Medical Imaging Study
Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Catamaran Resort, 3999 Mission Boulevard, San Diego, CA
92109.
Contact Person: Xiang-Ning Li, MD, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5112, MSC 7854, Bethesda, MD
20892, 301-435-1744, [email protected].
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Social Sciences and Population Studies A
Study Section.
Date: February 1, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Marines' Memorial Club & Hotel, 609 Sutter Street, San
Francisco, CA 94102.
Contact Person: Suzanne Ryan, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435-
1712, [email protected].
Name of Committee: Vascular and Hematology Integrated Review
Group; Atherosclerosis and Inflammation of the Cardiovascular System
Study Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Sheraton Delfina Santa Monica Hotel, 530 West Pico
Boulevard, Santa Monica, CA 90405.
Contact Person: Natalia Komissarova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD
20892, 301-435-1206, [email protected].
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Developmental Therapeutics Study Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Bayside, 4875 North Harbor Drive, San Diego,
CA 92106.
Contact Person: Sharon K. Gubanich, Ph.D., Scientific Review
Officer, Center for
[[Page 136]]
Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Room 6214, MSC 7804, Bethesda, MD 20892, (301) 408-9512,
[email protected].
Name of Committee: Risk, Prevention and Health Behavior
Integrated Review Group; Psychosocial Development, Risk and
Prevention Study Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Arlington, 1325 Wilson Boulevard, Arlington, VA
22209.
Contact Person: Anna L. Riley, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301-435-
2889, [email protected].
Name of Committee: Bioengineering Sciences & Technologies
Integrated Review Group; Biomaterials and Biointerfaces Study
Section.
Date: February 1-2, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Capital View, 2850 South Potomac Avenue,
Arlington, VA 22202.
Contact Person: Joseph D. Mosca, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158, MSC 7808, Bethesda, MD
20892, (301) 408-9465, [email protected].
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Kidney, Nutrition, Obesity and Diabetes
Study Section.
Date: February 1-2, 2018.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Marriott Wardman Park Washington DC Hotel, 2660 Woodley
Road NW, Washington, DC 20008.
Contact Person: Fungai Chanetsa, MPH, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3135, MSC 7770, Bethesda, MD
20892, 301-408-9436, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: December 26, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-28226 Filed 12-29-17; 8:45 am]
BILLING CODE 4140-01-P
